REG - Physiomics PLC - Result of WRAP Retail Offer

PhysiomicsAnnouncement

Wed 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260318:nRSR1894Xa&default-theme=true

RNS Number : 1894X  Physiomics PLC  18 March 2026

Unless otherwise defined herein, the capitalised terms used in this
announcement have the same meaning as those used in the Company's
announcements released on 17 March 2026.

 

18 March 2026

 

Physiomics Plc

("Physiomics" or the "Company")

 

Result of WRAP Retail Offer

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions is pleased to announce, further to the
announcements made on 17 March 2026, the completion of the WRAP Retail Offer,
at the same issue price as the previously announced Placing (together the
"Fundraise"). The WRAP Retail Offer, which closed at midday today, 18 March
2026, has raised aggregate gross proceeds of £110,000.00 through the issue of
a total of 27,500,000 new Ordinary Shares at a price of £0.004 per share,
alongside the previously announced Placing which raised gross proceeds of
£490,000.00.

 

The Fundraise, which is conditional only on Admission, raised gross proceeds
of, in aggregate, £600,000.00, via the issue of 122,500,000 Placing Shares
pursuant to the Placing and 27,500,000 WRAP Retail Offer Shares pursuant to
the WRAP Retail Offer.

 

Admission and Total Voting Rights

Applications have been made for the Placing Shares and the WRAP Retail Offer
Shares to be admitted to trading on AIM, which is expected to become effective
and dealings commence on or around 8.00 a.m. on 20 March 2026 ("Admission").

 

Following Admission, the Company's issued ordinary share capital will consist
of 453,208,718 Ordinary Shares. Since the Company currently holds no Ordinary
Shares in treasury, the total voting rights in the Company will be
453,208,718. These figures may be used by shareholders of the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

The new Ordinary Shares to be issued pursuant to the WRAP Retail Offer (which
is conditional on the Placing) will be issued free of all liens, charges and
encumbrances and will, on Admission, rank pari passu in all respects with the
new Ordinary Shares to be issued pursuant to the Placing and the Company's
existing Ordinary Shares.

 

 

 

For Further Information

 Physiomics plc                      +44 (0) 1235 841575
 Dr Peter Sargent, CEO

 Hybridan LLP (Broker)               +44 (0) 203 764 2341
 Claire Louise Noyce

 Strand Hanson Limited (NOMAD)       +44 (0) 20 7409 3494

 James Dance, James Bellman

 Winterflood Retail Access Platform  WRAP@winterflood.com
 Sophia Bechev, Kaitlan Billings     0203 100 0214

 

 

Further information on the Company can be found on its website at
www.physiomics.co.uk

 

The Company's LEI is 213800A71DSZ6ABMTQ91.

 

 Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIUWRSRNBUOAAR



            Copyright 2019 Regulatory News Service, all rights reserved